Clinical trials: Patients With Diabetes.
Type 2 Diabetes Mellitus, Hypercholesterolemia
Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.
This is a 16-week double-blind, placebo-controlled (for colesevelam hydrochloride (HCl)) study in the type 2 diabetic subjects and pre-diabetic subjects.
- Conditions
- Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
- Trial name
- NCT00570739
- Testing
- Metformin HCl tablets and Colesevelam tablets, Colesevelam
- Where
- 31 sites in United States, Colombia and 2 more
- Volunteers
- 502 people
- Sponsor
- Daiichi Sankyo
Diabetes
Study on the Effects on Blood Glucose Following Intradermal and Subcutaneous Dosing of Insulin in Diabetic Patients
The purpose of this study is to compare the effects of bolus delivery of insulin when delivered either intradermally (in the skin) or subcutaneously (under the skin) in diabetics.
- Trial name
- NCT01120444
- Testing
- BD Research Catheter with 34G x 1.5 mm needle, Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus, Type 2
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin.
- Trial name
- NCT05486065
- Testing
- Semaglutide
- Where
- 130 sites in United States, Greece and 3 more
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
NASH - Nonalcoholic Steatohepatitis, NAFLD
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
This is a randomized, placebo-controlled, four-arm, double-blind study. Subjects will be randomized (1:1:1:1) to receive either a daily oral placebo solution or a daily oral dose of 0.5 mg, 2.5 mg or 5.0 mg Foralumab Solution for…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAFLD, T2DM (Type 2 Diabetes Mellitus)
- Trial name
- NCT03291249
- Testing
- Foralumab, Omeprazole 20mg
- Sponsor
- Tiziana Life Sciences LTD
Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and delayed gastric emptying.
- Conditions
- Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications, Gastroparesis, Gastrointestinal Motility Disorder
- Trial name
- NCT01394055
- Testing
- RM-131
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Motus Therapeutics, Inc.
Diabetes Mellitus, Type 2
Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin
This trial will explore the various advantages and possible disadvantages of pioglitazone and insulin glargine when added to monotherapy.
- Trial name
- NCT00384215
- Testing
- insulin glargine [rDNA origin] injection
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- Sanofi
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Diabete Mellitus, Medical Device
Non-invasive Glucose Measurement With Raman Technology in Patients With Type 1 and Type 2 Diabetes
The study was established to collect data and reference measurements in order to establish calibration models for the Prototype 0.3
- Trial name
- NCT03781232
- Testing
- Prototype 0.3
- Where
- 2 sites in Germany
- Volunteers
- 47 people
- Sponsor
- RSP Systems A/S
Diabetes Mellitus, Type 2
Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
The objectives of this study are to monitor the safety and effectiveness of Esgliteo in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting.
- Trial name
- NCT05130463
- Testing
- Empagliflozin/Linagliptin
- Where
- 30 sites in South Korea
- Volunteers
- 1,053 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients
The primary objective was to demonstrate the superiority of insulin glargine over sitagliptin in reducing Glycosylated Hemoglobin A1c (HbA1c) from baseline to the end of the treatment period.
- Trial name
- EASIE (NCT00751114)
- Testing
- Insulin Glargine, Sitagliptin, Metformin
- Where
- 17 sites in United States, Austria and 15 more
- Volunteers
- 515 people
- Sponsor
- Sanofi
Renal Insufficiency,Type 2 Diabetes
Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient
The purpose of the study is to investigate the pharmacokinetics/pharmacodynamics and safety of SHR3824 in Type 2 Diabetes Patients with Renal Insufficient.
- Trial name
- NCT03159832
- Testing
- SHR3824
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Type 2 Diabetes Mellitus
Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
Primary Objective: To assess the effects on glycemic control of lixisenatide in comparison to placebo as an add-on treatment to basal insulin with or without metformin in terms of HbA1c reduction over a period of 24 weeks in…
- Trial name
- NCT01632163
- Testing
- Lixisenatide (AVE0010)
- Where
- 51 sites in China, India and 2 more
- Volunteers
- 447 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes
Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.
- Trial name
- NCT03817463
- Testing
- Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
- Where
- 13 sites in Denmark, Finland and 9 more
- Volunteers
- 327,624 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%
This study is not being conducted in the United States. This is a 52-week extension to a study to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, in lowering overall blood glucose levels in…
- Trial name
- NCT00138593
- Testing
- vildagliptin
- Where
- Switzerland
- Volunteers
- 180 people
- Sponsor
- Novartis
Diabetic Peripheral Neuropathy
DEXINEURO® Tab on Blood Glucose Reduction in Patients With Type 2 Diabetes Accompanied by Diabetic Peripheral Neuropathy
This study is to evaluate the efficacy of DEXINEURO® tab on blood glucose reduction and assess the interaction with concomitantly administered insulin or oral antidiabetic agents in patients with type 2 diabetes accompanied by…
- Trial name
- NCT06191614
- Where
- South Korea
- Volunteers
- 528 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Type 2 Diabetes
GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate
This is a 24-week study to determine the lipid metabolic effects, safety, and tolerability of tesaglitazar compared with metformin and metformin in combination with fenofibrate in patients with type 2 diabetes and low…
- Trial name
- NCT00261352
- Testing
- Tesaglitazar, Metformin, Fenofibrate
- Where
- 152 sites in Brazil, Canada and 16 more
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
This 3 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to placebo in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
- Trial name
- NCT00744926
- Testing
- taspoglutide
- Where
- 58 sites in United States, Australia and 9 more
- Volunteers
- 373 people
- Sponsor
- Hoffmann-La Roche
Hypertension
Bisoprolol in Hypertension: Effect on Concomitant Elevated Heart Rate
The b.p.m study will be performed to gain the insight in the courses of illness and therapy in subjects, suffering from hypertension and that have elevated heart rate.
- Trial name
- NCT01109043
- Testing
- Bisoprolol or bisoprolol + HCTZ
- Where
- Austria
- Volunteers
- 351 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular Age-Related Macular Degeneration.
- Trial name
- NCT04537884
- Testing
- UBX1325
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Unity Biotechnology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.